New drug IPG1094 gets first human test in china
NCT ID NCT07679113
First seen Jul 01, 2026 · Last updated Aug 11, 2026 · Updated 3 times
Summary
This phase 1 trial tests the drug IPG1094 in 24 healthy Chinese adults to understand how the body absorbs, processes, and eliminates it. Part A examines whether food affects a single dose, while Part B looks at repeated dosing over 10 days. All participants are monitored for safety and side effects.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- IPG1094
- What this could lead to
- If successful, this study will provide key data on how IPG1094 behaves in the body, supporting future trials for potential therapeutic uses.
- What could go wrong
- This is an early phase 1 trial in only 24 healthy volunteers, so results may not predict effects in patients. The drug may cause side effects or fail in later studies.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY VOLUNTEERS are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Shanghai Xuhui Central Hospital
RECRUITINGShanghai, Xuhui, 200031, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a new oral drug pass its first safety hurdle?
- Can a new drug play nice with common medicines? a trial investigates
- Could a new pill quiet chronic pain? early trial puts it to the test
- Brain waves under pressure: can light uncover the signature of mental work?
- Can acting as patients teach nurses to truly listen?
- Who decides for you? survey asks incarcerated older adults